Cargando…

A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients

BACKGROUND AND AIMS: Extremely elevated levels of low-density lipoprotein-cholesterol (LDL-C) contribute to long-term chronic systemic inflammation in homozygous familial hypercholesterolemia (HoFH) patients. The aims of this study is to describe the inflammatory profile of HoFH patients and explore...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fangyuan, Ye, Pucong, Hao, Yu, Du, Juan, Zhang, Hang, Wang, Zengtao, Wang, Xumin, Zeng, Hui, Ma, Yaluan, Lin, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833253/
https://www.ncbi.nlm.nih.gov/pubmed/36644203
http://dx.doi.org/10.1016/j.athplu.2022.05.002
_version_ 1784868199173455872
author Li, Fangyuan
Ye, Pucong
Hao, Yu
Du, Juan
Zhang, Hang
Wang, Zengtao
Wang, Xumin
Zeng, Hui
Ma, Yaluan
Lin, Jie
author_facet Li, Fangyuan
Ye, Pucong
Hao, Yu
Du, Juan
Zhang, Hang
Wang, Zengtao
Wang, Xumin
Zeng, Hui
Ma, Yaluan
Lin, Jie
author_sort Li, Fangyuan
collection PubMed
description BACKGROUND AND AIMS: Extremely elevated levels of low-density lipoprotein-cholesterol (LDL-C) contribute to long-term chronic systemic inflammation in homozygous familial hypercholesterolemia (HoFH) patients. The aims of this study is to describe the inflammatory profile of HoFH patients and explore the effect of a PCSK9 inhibitor (PCSK9i) on a series of inflammatory biomarkers, including the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-HDL ratio (MHR), monocyte-lymphocyte ratio (MLR) and mean platelet volume-lymphocyte ratio (MPVLR). METHODS: In this prospective cohort study, 25 definitive HoFH patients on high-intensity statins plus ezetimibe were administered subcutaneous injections of 420 mg PCSK9i every 4 weeks (Q4W). The biochemical parameters and inflammatory profile were analyzed on the day before PCSK9i therapy and 3 months and 6 months after PCSK9i therapy. RESULTS: HoFH on the maximum tolerated statin dose plus ezetimibe displayed elevated lipid and disturbed blood biomarker profiles. After 3 months of add-on PCSK9i therapy, a significant reduction in LDL-C was observed. Moreover, the percentage and count of neutrophils, monocyte counts, MPV, and two inflammatory biomarkers, the NLR and MLR, were reduced. However, at 6 months of PCSK9i treatment, the NLR and MLR returned to pre-PCSK9i treatment levels. CONCLUSIONS: PCSK9i induces a transient decrease in the NLR and MLR in HoFH patients in a lipid-lowering independent manner.
format Online
Article
Text
id pubmed-9833253
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98332532023-01-12 A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients Li, Fangyuan Ye, Pucong Hao, Yu Du, Juan Zhang, Hang Wang, Zengtao Wang, Xumin Zeng, Hui Ma, Yaluan Lin, Jie Atheroscler Plus Full Length Article BACKGROUND AND AIMS: Extremely elevated levels of low-density lipoprotein-cholesterol (LDL-C) contribute to long-term chronic systemic inflammation in homozygous familial hypercholesterolemia (HoFH) patients. The aims of this study is to describe the inflammatory profile of HoFH patients and explore the effect of a PCSK9 inhibitor (PCSK9i) on a series of inflammatory biomarkers, including the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-HDL ratio (MHR), monocyte-lymphocyte ratio (MLR) and mean platelet volume-lymphocyte ratio (MPVLR). METHODS: In this prospective cohort study, 25 definitive HoFH patients on high-intensity statins plus ezetimibe were administered subcutaneous injections of 420 mg PCSK9i every 4 weeks (Q4W). The biochemical parameters and inflammatory profile were analyzed on the day before PCSK9i therapy and 3 months and 6 months after PCSK9i therapy. RESULTS: HoFH on the maximum tolerated statin dose plus ezetimibe displayed elevated lipid and disturbed blood biomarker profiles. After 3 months of add-on PCSK9i therapy, a significant reduction in LDL-C was observed. Moreover, the percentage and count of neutrophils, monocyte counts, MPV, and two inflammatory biomarkers, the NLR and MLR, were reduced. However, at 6 months of PCSK9i treatment, the NLR and MLR returned to pre-PCSK9i treatment levels. CONCLUSIONS: PCSK9i induces a transient decrease in the NLR and MLR in HoFH patients in a lipid-lowering independent manner. Elsevier 2022-05-18 /pmc/articles/PMC9833253/ /pubmed/36644203 http://dx.doi.org/10.1016/j.athplu.2022.05.002 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Full Length Article
Li, Fangyuan
Ye, Pucong
Hao, Yu
Du, Juan
Zhang, Hang
Wang, Zengtao
Wang, Xumin
Zeng, Hui
Ma, Yaluan
Lin, Jie
A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients
title A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients
title_full A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients
title_fullStr A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients
title_full_unstemmed A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients
title_short A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients
title_sort pcsk9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833253/
https://www.ncbi.nlm.nih.gov/pubmed/36644203
http://dx.doi.org/10.1016/j.athplu.2022.05.002
work_keys_str_mv AT lifangyuan apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT yepucong apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT haoyu apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT dujuan apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT zhanghang apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT wangzengtao apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT wangxumin apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT zenghui apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT mayaluan apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT linjie apcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT lifangyuan pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT yepucong pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT haoyu pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT dujuan pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT zhanghang pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT wangzengtao pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT wangxumin pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT zenghui pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT mayaluan pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients
AT linjie pcsk9inhibitorinducesatransientdecreaseintheneutrophillymphocyteratioandmonocytelymphocyteratioinhomozygousfamilialhypercholesterolemiapatients